| Title: | Breast Cancer and Hormone Suppression Study |
| Purpose: | The research is being done to determine if supressing ovary function during chemotherapy can reduce the incidence of premature menopause, which is often caused during adjuvant chemotherapy for breast cancer. |
| Study Number: | 107001 |
| Number of Patients: | 416 |
| Elgibility: |
Eligible patients must be between 18 to 50 years old; have had surgery to remove all of the tumor and plan for chemotherapy after surgery; have a specific type of receptor status of tumor (which is determined by the pathologist); can have had surgery more than 84 days of when you will be registered; no history of prior cancer or prior chemotherapy. Patients must be able to perform most or all of self care activities.
|
| Treatment: | Patients will be placed in one of two groups (randomized study). Group 1 will receive the planned post-operative chemotherapy for breast cancer. Group 2 also will receive chemotherapy but will receive a hormone injection given through a needle just under the skin. This injection will be given one week before chemotherapy starts and will continue once every four weeks for the length of chemotherapy |
| Principal Investigator: |
Kathy S. Albain, M.D. |
| Enrollment Phone: | (708) 327-3222 |
| |
| |
| |
|
